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Abstract: Cardiovascular disease (CVD) is a multifactorial disease that involves
the interplay of many risk factors. Traditional risk factors as defined by the
American Heart Association fail to account for all instances of atherosclerosis
and CVD. Only within the last 100 years have infectious diseases gained
prominence as potential risk factors for cardiovascular illnesses. Within the last
50 years, Chlamydiae pneumoniae, a pervasive intracellular pathogen, has been
implicated in the development of atherosclerosis and CVD. This investigation
aimed to clarify the relationship between Chlamydia pneumoniae (C.
pneumoniae) and CVD. This task was accomplished through in-depth research
within the literature of PubMed, using Koch’s postulates as guidelines to
determine the role of C. pneumoniae in cardiovascular disease. Findings from
this investigation suggest a causative relationship between C. pneumoniae and
CVD. In addition to traditional risk factors, this investigation found C. pneumoniae
to be a risk factor in the development of atherosclerosis and ensuing
cardiovascular disease.
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Introduction
According to the American Heart Association, as of 2017, cardiovascular
disease remains the number one cause of death within the United States, and
includes death by stroke, heart disease, and other cardiovascular illnesses. The
American Heart Association reports an astonishing 85.6 million people suffer
from ≥1 type of cardiovascular disease, and in 2013, 800,237 deaths in the
United States were the direct result of complications due to cardiovascular
disease. The 2017 update by the American Heart Association regarding
cardiovascular disease in America estimates a financial burden of 316.6 billion
dollars1. In addition to being the number one cause of death in the United States,
cardiovascular disease remains the number one cause of global morbidity2.
Traditional risk factors for cardiovascular disease include tobacco use, physical
inactivity, family history and genetics, metabolic syndrome, diabetes, obesity,
high blood pressure, abnormal blood lipid levels, poor nutrition, and chronic
kidney disease1. Atherosclerosis is a chronic, inflammatory process
characterized by constriction of arteries and veins within the cardiovascular
system and is the primary pathological mechanism of cardiovascular disease
development. Numerous studies have validated traditional risk factors as
contributors to atherosclerosis and cardiovascular illness. Within the last 50
years, numerous infectious diseases including Epstein-Barr virus,
Cytomegalovirus, Porphyromonas gingivalis and Chlamydia pneumoniae have
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been implicated in the development of atherosclerosis and cardiovascular
disease3.
Cardiovascular Disease:
Broadly defined, cardiovascular disease entails diseases of the heart and
blood vessels and includes, but is not limited to: coronary artery disease,
cerebrovascular disease, peripheral artery disease, rheumatic heart disease,
deep vein thrombosis and pulmonary embolism, and congenital heart disease.
Globally, cardiovascular disease (CVD) is the number one cause of death, with
an estimated 17.9 million deaths per year directly resulting from CVD4.
Cardiovascular disease is listed as the underlying cause of death in
approximately one out of every three deaths within the United States.
Additionally, the global financial burden of CVD in 2011 was estimated at $863
billion, and is expected to rise to 1,044 billion dollars by 20304. Cardiovascular
diseases are multifactorial, progressive diseases frequently warranting medical
treatment when lifestyle changes fail to improve cardiovascular health
adequately.
Heart Attack (myocardial infarction):
A heart attack occurs when constriction and blockage within the coronary
arteries stop the delivery of oxygen-rich blood to the heart muscle, causing death
of heart muscle tissue. Myocardial infarction is a life-threatening acute condition
requiring immediate hospitalization and medical intervention. There are an
estimated 720,000 new cases of heart attack annually in the United States
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alongside 335,000 recurrent heart attack episodes. Coronary artery disease
(CAD) is defined as the narrowing of the primary arteries that supply the heart
with blood. The progressive narrowing of such arteries can lead to a heart attack;
every 40 seconds an American will suffer a heart attack. Heart attack and other
complications caused by coronary artery disease account for 1 in 7 deaths within
the United States1. In 2015, heart attacks claimed the lives of 114,023
Americans, with an annual associated treatment cost exceeding 12 billion dollars;
making heart attack the most expensive condition to treat within the American
health care system1.
Stroke:
Stroke occurs when arteries that supply blood to the brain become
obstructed or rupture. Stroke is a leading cause of disability within the United
States and kills nearly 133,000 people per year. Similarly, an American will suffer
a stroke every 40 seconds, will die of a stroke every 3 minutes and 45 seconds,
and in 2015 stroke accounted for 11.8% of the total deaths worldwide1.
Hypertension:
Hypertension is a state of chronic high blood pressure. High blood
pressure increases the workload on the heart to push blood through the arteries.
The compensatory force can cause damage to the endothelium within the
arteries, resulting in a cascade of events that propagates atherosclerosis, the
buildup of plaque on the endothelial surfaces, and subsequent constriction of the
arteries and veins. Hypertension affects more than 100 million Americans and is
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a major contributor to cardiovascular health decline and disease1. The estimated
direct and indirect costs of treatment in the US for hypertension is 73.4 billion
dollars5. With such a high cost of life and substantial financial burden,
understanding, treating and preventing cardiovascular disease is of paramount
importance.
Figure 1: Annual death rate per 100,000 in the United States resulting from coronary heart
disease, stroke, and total cardiovascular diseases within the United States1.

Figure 2: Total cost in billions of dollars to treat the major cardiovascular disease types within the
United States1.
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Ideal Cardiovascular Health and Prevention:
In 2009, the American Heart Association (AHA) established a set of
recommendations, known as impact goals, to reduce the prevalence of
cardiovascular disease by 20% before 2020. Additionally, such impact goals aim
to reduce deaths caused by cardiovascular diseases and stroke by 2020.
Instrumental in the realization of the 2020 impact goals are seven key factors,
identified as mediators of cardiovascular health. Such factors are used as
guidelines set by the AHA to model ideal cardiovascular health. Each factor is
assigned a range of values that are considered the optimal range for
cardiovascular health as defined by the American Heart Association. The seven
key factors are blood pressure, physical activity, fasting cholesterol levels, diet,
weight, tobacco use, and fasting blood glucose levels.

Table 1: Seven factors and associated ranges for cardiovascular health as defined by the
American Heart Association in conjugation with the Impact Goals of 20206. All data represented
are reflective of parameters outlined for adults greater than 20 years of age.

AHA Metric

Ideal Cardiovascular Health Definition

Tobacco Use
Body Mass Index
Physical Activity

Never tried or quit >12 months ago
< 25kg/m2
≥ 150min per week moderate intensity or ≥ 75min per
week vigorous intensity or combination
1) Fruits and Vegetables: ≥ 4.5 cups per day
2) Fish: ≥ 3.5 oz per week (oily fish)
3) Fiber Rich Whole Grains: ≥ 1.1 g of fiber per 10g of
carbohydrates ≥ 3 1oz servings per day
4) Sodium: < 1500 mg per day
5) Sugar-sweetened beverages: ≤ 450 kcal (36oz) per
week

Health Diet Score

Total Cholesterol
(LDL+HDL)
Blood Pressure
Fasting Plasma Glucose

< 200mg/dl
< 120/ < 80 mmHg
< 100 mg/dl
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Atherosclerosis: The Mechanism of CVD:
Atherosclerosis is the thickening of arterial walls causing partial or
complete blockage of blood flow. Atherogenesis is initiated in response to
endothelial damage within the artery, leading to a lesion formation within the
endothelium known as a fatty streak. Establishment of a fatty streak is indicative
of early-stage atherosclerotic disease, consisting primarily of monocyte-derived
macrophages and T-lymphocytes 7. Cells within the developing lesion release
chemical mediators that induce proliferation of smooth muscle cells and
formation of an extracellular tissue matrix, initiating a progressive inflammatory
response8, 9. Oxidized, circulating lipids are internalized via scavenger receptors
by macrophages within the lesion, leading to the formation of foam cells7. The
development of such foam cells promotes recruitment and influx of circulating
monocyte-derived macrophages that release cytokines, growth factors and
hydrolytic enzymes that further damage the endothelium. The continued
proliferation of smooth muscle cells and the evolution of fibrous tissues within the
lesion are characteristic of a chronic, more advanced intermediate lesion. The
continued release of cytokines, prostaglandins, and other inflammatory mediators
further aggravate the endothelium. The end result is a cyclical process of
endothelial damage, influx of leukocytes, cytokine and chemical mediator
release, foam cell proliferation, lipid accumulation, further endothelial damage
and increased inflammation. Over time, chronic inflammation facilitates fibrous
tissue formation and the advancement of a large, complex-lesion that
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encroaches upon the lumen of the endothelium, initiating the development of
cardiovascular disease.
Cardiovascular Disease and the Current Model of Understanding:
Risk factors for CVD include diabetes, hypertension, metabolic syndrome,
tobacco use, diet and exercise parameters, genetic abnormalities, and infectious
diseases 1, 10-12. Atherosclerosis is an inflammatory disease and the primary
pathophysiological mechanism of cardiovascular dysregulation. The current
model of the genesis and progression of CVD involves an interplay of
independent and associated risk factors. Although the aforementioned traditional
risk factors are associated with the development of CVD, they do not account for
the total incidence of cardiovascular diseases, generating the need for a broader,
more comprehensive understanding3, 12-14.
Figure 3: Tradition risk factors associated with the development of atherosclerosis and
subsequent cardiovascular disease. Such traditional risk factors do not account for the total
incidence of cardiac disease15-18.
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Infectious Diseases and Chlamydia pneumoniae:
Infectious diseases were first recognized as potential risk factors for the
development of atherosclerosis in 1978 when Marek’s disease herpesvirus was
shown to cause atherosclerosis in chickens15. Since that time, numerous bacteria
and viruses including Helicobacter pylori Cytomegalovirus, Porphyromonas
gingivalis, and Chlamydia pneumoniae (C. pneumoniae) have been associated
with the development or progression of atherosclerosis and CVD11. However,
such associations are rather loose, and the mechanisms by which such
infectious agents play a role in the development, and progression of
atherosclerosis and CVD remains unclear. Chlamydia pneumoniae was first
established as a potential risk factor for CVD when the bacteria were detected in
coronary arterial fatty streaks and lesions16, 17. Since that time, the organism has
garnered considerable attention as another potential risk factor for the
development of atherosclerosis and CVD. This paper hypothesizes that there is
sufficient evidence within the literature to establish an association between
Chlamydia pneumoniae and the genesis, progression, sustainment or
aggravation of atherosclerosis and subsequent cardiovascular disease.
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Figure 4: Proposed interplay between traditional risk factors, infectious diseases, and Chlamydia
pneumoniae infections as independent and associated risk factors contributing synergistically in
the development of cardiovascular disease.
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Methods
A systematic and in-depth review of the literature will be conducted within
PubMed, regarding C. pneumoniae and any important links to cardiovascular
disease. This paper will explore known mechanisms involved in CVD, infectious
diseases implicated in CVD, Koch’s postulates regarding C. pneumoniae and
CVD. This paper intends to establish and understand the role, if any, played by
the infectious disease C. pneumoniae in CVD, and demonstrate how such an
understanding may lead to potential therapeutic targets and better medical
outcomes regarding cardiovascular diseases.
Literature Review
Infectious Disease and Cardiovascular Disease:
Human cytomegalovirus was one of the first infectious diseases garnering
attention as a potential contributor to atherosclerosis when Fabricant et al.

10

established a link between Herpes virus infections and atherosclerosis via
experimental animal models18. Further corroboration of the link between human
cytomegalovirus (CMV) and atherosclerosis was elucidated through a serological
study that demonstrated higher titer concentrations of CMV, herpes simplex virus
type-1 (HSV1), and herpes simplex virus type-2 (HSV2) antibodies present in
patients undergoing vascular surgery for atherosclerosis19 than in control
patients. The presence of CMV, HSV1 and HSV2 antibodies is consistent with
chronic infections that induce inflammatory processes within the vasculature,
leading to atherosclerosis. Multiple studies solidified the link between virally
induced atherosclerosis and cardiovascular disease20, 21.
Helicobacter pylori is a gram-negative bacterium and the causative agent
of gastric ulcers. H. pylori has only recently come to light as a possible
contributor to the development of cardiovascular disease, as one study indicated
a drastic reduction in heart attacks paralleled the reduction of duodenal ulcers
caused by H.pylori22. Serological evidence found a positive association between
the presence of H. pylori antibodies (HSP) or antibodies respondent to CagA, a
virulence factor of H. pylori, and an increased risk of the development of
atherosclerosis and coronary artery disease. Such studies determined that H.
pylori infection is an independent risk factor for coronary artery disease 23, 24.
However, such a conclusion has been disputed by experimental results that
yielded no such association25, 26. The relationship between H. pylori infectious
burden and cardiovascular disease remains ambiguous.
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Oral pathogens have also been linked to cardiovascular diseases,
primarily affecting immunocompromised patients. Periodontal disease, an
infection in the gums that may result in tooth and bone loss, is a condition
fostered by poor oral hygiene and microbial overgrowth. Actinobacillus
actinomycetemcomitans, tannerella forsythensis, Porphyromona gingivalis,
Prevotella intermedia, and Treponema denticola are pathogenic organisms that
cause periodontal disease27, 28. One study by Spahr et al. found that total
pathogen burden in periodontal disease was a predictor for a coronary event.
Spahr et al. concluded that pathogenic burden (total amount of microbes present)
is an independent risk factor for cardiovascular disease. Authors of the study also
postulated that the number of A. actinomycetemcomitans microbes present
within periodontal pockets was also a statistically significant predictor of coronary
heart disease27. Porphyromonas gingivalis is another periodontal pathogen linked
to cardiovascular disease. A study conducted by Ghizoni et al. found increased
levels of P. gingivalis within the gingival pockets of 20 stroke patients, supporting
a relationship between P. gingivalis and cerebral infarction28. Collectively, the
majority of studies regarding periodontal disease and cardiovascular illness
assert that pathogenic burden within periodontal disease is an independent risk
factor for cardiovascular disease27, 28.
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Koch’s Postulates:
Koch’s postulates are a set of guidelines used to establish a causative
relationship between a microorganism and a disease. They are summarized in
the table below.
Table 2: Definitions of Koch’s Postulates.

Postulate

Definition

Koch’s 1st Postulate

Microorganisms should be found in heavy
abundance in all disease hosts, and absent in
healthy organisms.

Koch’s 2nd Postulate

Microorganism must be isolated from diseased
host, and grown in pure culture.

Koch’s 3rd Postulate

Microorganism must cause associated disease
when introduced into healthy organism.

Koch’s 4th Postulate

Microorganism must be re-isolated from
diseased, experimental host and determined to
be identical to original causative agent.

Chlamydia pneumoniae: Infection, Isolation, and Detection:
Chlamydia pneumonia was first isolated from the conjunctiva of a
Taiwanese child, and later on in another case, isolated as a respiratory sample
from a patient with pharyngitis29, 30. The newly acquired pathogenic strain was
labeled TWAR, in reference to the first two clinical isolates and was established
as the third Chlamydial species31. Chlamydia pneumoniae is a gram-negative
intracellular bacteria responsible for an average of 10% of community-acquired
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pneumonia31.Transmission is believed to occur through direct contact with
respiratory secretions from infected hosts. Clinical manifestations of C.
pneumoniae infection mimic that of a sinus infection and include, malaise,
coughing, pharyngitis and slow recovery time31; more severe and systemic
infections are unusual, but have been documented 32. Prior to invasion of host
cells, C. pneumoniae exists as a smaller, biologically inactive extracellular form
called an elementary body (EB). Elementary bodies are phagocytosed by host
cells and undergo transformation into a larger, replicating form known as an
inclusion body31. Elementary bodies are pear-shaped when viewed under a
microscope and are indicative of C. pneumoniae infection. Observation of either
elementary bodies via microscopy, or inclusions bodies conjugated with
fluorescein, is an effective method of C. pneumoniae detection within clinical
isolates31. Isolation and growth of C. pneumoniae as a pure culture has been
only mildly successful. Such limited success could be due in part to the rapid
decay in viability of C. pneumoniae at room temperatiure33. Culturing of C.
pneumoniae has been successful within chicken eggs, and more fastidious
strains of C. pneumoniae have been grown within HL cells and HEp-2 cell
monolayers31, 34, 35. The incorporation of cycloheximide, a eukaryotic protein
synthesis inhibitor, into culture media has been utilized to inhibit host cell activity
and increase C. pneumoniae isolation success31. Since culturing and isolation of
C. pneumoniae often fails, other methods for the detection of C. pneumoniae
have been implemented. The primary serological test for the detection of C.
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pneumoniae is the microimmunofluorescence test (MIF test). The MIF test is able
to detect IgM and IgG antibodies specific to C. pneumoniae, and is considered
positive when there is a fourfold increase in IgA or IgM titers, compared to
noninfected individuals. The appearance of IgM and IgG antibodies are slow and
generally take 3-4 weeks to be detected31. Species-specific antigen detection
that uses monoclonal antibodies coupled with fluorescent labels
(immunohistochemistry) has been used to detect C. pneumoniae within cell
culture 31. Additionally, other antibody detection methods have been applied
(ELISA) to detect the presence of C. pneumoniae. Polymerase chain reaction
(PCR ), utilizing C. pneumoniae specific DNA probes, is also used as to detect C.
pneumoniae from clinical samples and is frequently coupled with serological
testing. Multiple DNA probes can replicate rRNA sequences, gene sequences
unique to C. pneumoniae (MOMP and Omp1 genes), and a 60 kDa cysteine-rich
protein of C. pneumoniae. Collectively, serological testing (MIF), antigen
detection (ELISA), PCR , and the observation of elementary/inclusion bodies are
the primary means of detection for C. pneumoniae31. This investigation will try to
oblige by strict parameters outlined by Koch’s postulate, however, since isolation
of C. pneumoniae in pure culture is so difficult, detection with the aforementioned
techniques should be considered sufficient when trying to establish Koch’s
postulates and the relationship between C. pneumoniae and atherosclerosis.
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Chlamydia pneumoniae, CVD, and Koch’s 1st Postulate:
To determine if there is enough evidence to satisfy Koch’s first postulate,
studies were reviewed within this investigation that utilized PCR,
immunohistochemistry or microimmunofluorescence as primary detection
methods; as such methods are taken to be the most reliable in detecting the
presence of C. pneumoniae within atherosclerotic lesions and host serum.
Davidson et al. conducted a study in which coronary artery tissues were
harvested post-mortem from 60 indigenous Alaska Natives and examined for the
presence of C pneumonia. Subjects were labeled as low-risk for coronary artery
disease, and 97% of subjects had died from non-cardiovascular causes36. Of
note, all of the samples harvested from subjects contained some atherosclerotic
tissue, and polymerase chain reaction or ICC detected Chlamydia pneumonia
within coronary fibro-lipid atheromas in 15 of 60 harvested samples. Additionally,
7 of 60 samples tested positive for the bacterium within early flat lesions of
coronary artery tissues. The odds ratio, a quantitative measure of association
between exposure and outcome, for C. pneumonia in tissues with raised
atheroma lesions was assigned a value of 6.1, which asserts that the presence of
C. pneumoniae is statistically associated with that of raised atheromatous
lesions. From the detection of C. pneumoniae within atheromas via PCR and
ICC, investigators concluded that C. pneumoniae present in serum precedes
coronary atherosclerosis36.

16

Kuo et al. autopsied 36 South African individuals 8-36 hours after death
and harvested coronary artery tissues. Samples were collected from individuals
who had died from traumatic accidents. Atherosclerotic lesions from coronary
samples were analyzed for the presence of C. pneumoniae using PCR that
amplified 16sribosomal RNA sequences unique to C .pneumoniae. Additionally,
immunohistochemistry was used to detect C. pneumoniae in coronary artery
atheromas. Chlamydia pneumonia was detected within atheromas by
immunohistochemistry in 15 of 36 cases and by PCR in 13 of 30 cases. Further
confirmation was attained when six atheroma lesions were analyzed using
electron microscopy, and visual confirmation was attained for C. pneumoniae-like
organisms; such organisms are described as pear shaped16.
In a compelling study, 105 Iranian patients had undergone coronary
bypass grafting and provided coronary artery samples to be analyzed by PCR for
the presence of C. pneumoniae. Of those patients, 53 non-atherosclerotic
mammillary arteries, were also collected and tested for C. pneumoniae as
controls. Of the 105 patients, 23 patients tested positive for the presence of C.
pneumoniae in atherosclerotic plaques within coronary samples. Importantly,
PCR results were negative in all 53 control mammillary arteries for the presence
of C.pnuemoniae37.
Haider et al. searched for C. pneumoniae in 63 patients diagnosed with
concurrent angina and myocardial infarction. An additional 40 subjects were
assessed for the presence of C. pneumoniae as healthy controls. Polymerase
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Chain Reaction for 16 SrRNA was utilized to detect C. pneumoniae within blood
samples. Serum samples were analyzed via ELISA for species-specific IgA
antibodies as an indirect detection of C. pneumoniae. Immunoglobulin-A
antibodies were detected in 66.66% of cardiovascular disease patients compared
to just 41.37% in control groups. Of 40 cardiovascular disease patients, 32.5%
tested positive for the presence of C. pneumoniae within the serum using PCR
detection analyses, 76.92% of which also tested positive for C. pneumoniae IgA
antibodies during serological testing38.
A cross-sectional study conducted in 2015 looked at 85 patients referred
for coronary bypass grafting for the presence of C. pneumoniae. In this
investigation, nesting PCR for Pst1 fragment was utilized as a metric for the
presence of C. pneumoniae. Importantly, 25 out of 85 patients tested positive
using the methods mentioned above for the presence of C. pneumoniae within
atherosclerotic plaques; this is in comparison to only 5 out of 85 control group
patients that were referred for thoracic biopsy39.
A 2005 study involving 303 persons aimed to determine if C. pneumoniae
was present more frequently in patients with atherosclerosis compared to healthy
adults. Serum samples were obtained from 188 patients with diagnosed
atherosclerosis and 115 healthy patients. Samples were analyzed via ELISA for
the presence of IgA and IgG C. pneumoniae antibodies. For atheroma patients,
63.8% and 49.9% tested positive for IgA and IgG. In non-atheroma patients,
46.9% and 54.8% tested positive for IgG and IgA respectively. A statistically
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significant difference was found between the prevalence of C. pneumonia
antibodies within atherosclerotic, and non-atherosclerotic patients40.
In 2004 Sessa et al. utilized semi-nested PCR to determine if C.
pneumoniae was present in both atherosclerotic and non-atherosclerotic tissues
of the coronary arteries harvested at autopsy41. Three arterial segments were
collected from each of 60 patients, totaling 180 samples. Additionally, 30 healthy
coronary arteries were taken as control samples. Chlamydia pneumoniae was
detectable by PCR in atherosclerotic coronary arteries in 19 of 60 samples
examined, and not detectable in any of the 30 non-atherosclerotic 41.
Despite promising results to satisfy Koch’s first postulate, there have been
numerous studies that have been unable to detect C. pneumoniae in
atherosclerotic patients. Agmon et al. conducted a study looking at 385 subjects,
with atherosclerosis, undergoing transesophageal echocardiography, to evaluate
the presence of C. pneumoniae IgG antibodies in blood samples 42. Of the 385
samples taken, IgG specific C. pneumoniae antibodies were detected within the
serum of only 287 subjects. Fifty-eight patients were found to have low antibody
titers, 144 had intermediate antibody titers, and high antibody titers were found in
only 85 subjects. After statistical adjustments for confounding variables, it was
determined that C. pneumoniae antibody titers were not associated with the
presence of aortic plaques42.
Altman et al. assayed C. pneumoniae specific IgG antibodies utilizing
indirect immunofluorescence detection methods in the serum of 159 (arterial
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group) patients with severe arterial disease. Additionally, a second group of 203
patients with heart valve prostheses (valvular group) and no signs of coronary
heart disease (CHD) were also included in the study and assayed for C.
pneumoniae antibodies43. Patients of both groups were monitored over the
course of 2 years for fatal, non-fatal and systemic thrombotic events. One
hundred and seven patients within the arterial group (67.3%), and 120 (59.1%) in
the valvular group tested positive for C. pneumoniae antibodies. Atman et al.
reported 23 patients within the arterial group had fatal or non-fatal vascular
events, and only two patients within the valvular group had fatal, or non-fatal
vascular events. The prevalence of C. pneumoniae antibody was nearly equal in
arterial/valvular groups; importantly, the number of clinical events in positive
patients (227) and C. pneumoniae negative patients (135) was found to be the
same. Altman et al. concluded that C. pneumoniae infection is not an
independent risk factor for arterial disease43.
Hagiwara et al. tested for the presence of C. pneumoniae in
atherosclerotic plaques from 50 Japanese patients that had undergone carotid
endarterectomy, using ELISA and immunohistochemistry for C. pneumoniae 44.
Detection of antibodies IgG or IgA was also determined via blood samples.
Chlamydia pneumoniae IgG antibodies were detected in 24 (48%) patients within
the study. Chlamydia pneumoniae IgA antibodies were detected in 29 (58%).
Additionally, 8 (16%) patients were immunocytochemically positive for a
monoclonal antibody specific for C. pneumoniae. Despite seropositivity and
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immunohistochemical detection, frequency of stenosis, ulcerative plaques, or
symptomatic plaques was not increased in these patients44. Hagiwara et al.
concluded that C. pneumoniae is not a contributor to carotid atherosclerosis
within the Japanese population.
Chlamydia pneumoniae, CVD, and Koch’s 2nd Postulate:
Chlamydia pneumoniae is an obligate-intracellular pathogen that infects
eukaryotic cells, and a fastidious microbe difficult to isolate and maintain in cell
culture45. Pharyngeal swabs of C. pneumoniae must be transferred immediately
to a specialized Chlamydial transport medium and refrigerated, as the cells
deteriorate at room temperature31. In addition to being a highly fastidious and
slow-growing organism, C. pneumoniae form smaller inclusion bodies than other
Chlamydial species, making culture and identification all the more difficult31.
Despite these challenges, C. pneumoniae has been grown and passed
successfully within HEp-2 cells lines.45 During the course of this review, it has
been noted that detection of C. pneumoniae in patients with cardiovascular
disease has relied exclusively on serological testing, immunohistochemistry,
electron microscopy, amplification of 16sRNA, MOMP gene, or other gene
sequences specific to C. pneumoniae via nested, or semi-nested PCR. Few
studies have attempted to directly culture C. pneumoniae from the atherosclerotic
tissue of patients with cardiovascular disease. This result is most likely due to the
challenges of culturing and isolating C. pneumoniae in the laboratory. Despite an
extensive search within the literature of Pubmed, only two studies reported
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successful isolation of viable C. pneumoniae directly from atherosclerotic tissues
in patients suffering cardiovascular disease46, 47.
The study by Ramirez et al. aimed to link atherosclerosis and C.
pneumoniae by asserting, that if a causative relationship between C.
pneumoniae and atherosclerosis does exist, viable bacteria should be found
within atherosclerotic tissue 47. Ramirez and colleagues collected coronary
arteries from explanted hearts of twelve patients undergoing heart transplant
surgery. Segments of the coronary arteries were collected and transferred with
care via Chlamydial transfer buffer for isolation at three separate laboratories.
They report the HEp-2 monolayers were successfully infected with C.
pneumoniae. Polymerase chain reaction, immunohistochemistry, in situ
hybridization, electron microscopy, and serological testing were performed for
detection and identification of C. pneumoniae from the samples collected. Twelve
patients participated in the study, of which ten patients were diagnosed with
atherosclerosis of coronary arteries47. Importantly, C. pneumoniae was isolated
from a single patient (patient three) using HEp-2 cells as described by Roblin et
al45. Three culturing sites/laboratories successfully isolated C. pneumoniae from
samples harvested from the same patient. The isolated bacterium was confirmed
as C. pneumoniae through species-specific monoclonal antibody detection,
detection of inclusion bodies in HEp-2 cells via electron microscopy, and
sequencing of the omp1 gene for comparison to published sequences of C.
pneumoniae.
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Jackson et al. accomplished the second successful isolation of C.
pneumoniae from atherosclerotic tissue46. Chlamydia pneumoniae was isolated
from patients undergoing carotid endarterectomy, a procedure involving removal
of large amounts of atheromatous tissue46. The study included 25 patients who
had undergone carotid endarterectomy, and similar to the findings of Rameriz et
al., only a single isolation of C. pneumoniae was successful from the harvested
atherosclerotic tissue. The culture was isolated after six days of incubation and
was confirmed as C. pneumoniae through species specific-monoclonal antibody
reactivity. Successive passage of C. pneumoniae in HL cells yielded
characteristic inclusion bodies, and further identification was provided via
observation of a pear-shaped morphology under electron-microscopy46.
Chlamydia pneumoniae isolated from atherosclerotic plaques by Jackson et al.
was confirmed to be identical to clinical respiratory C. pneumoniae isolates by
DNA hybridization and PCR. The results of the experiment by Jackson et al.
further establishes an association of C. pneumoniae and cardiovascular disease
by demonstrating the presence of viable bacteria within atherosclerotic tissue
and assists in satisfying Koch’s second postulate.
Chlamydia pneumoniae, CVD, and Koch’s 3rd Postulate:
Many studies have satisfied a modified version of Koch’s third postulate;
meaning microbes confirmed as C. pneumoniae through microbiological testing,
have been inoculated into animal models and demonstrated to induce
atherosclerotic lesions. The most significant studies aiming to solidify the
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relationship between C. pneumoniae and atherosclerosis, and satisfy Koch’s 3rd
postulate are described below.
Muhlestein et al. utilized direct intravascular inoculation of C. pneumoniae
into the aortas of rabbits via a drug delivery catheter to test the potential for C.
pneumoniae to cause atherosclerosis. 48 Inclusion-forming units of C.
pneumoniae were directly injected into the abdominal wall of the aorta and
rabbits were subsequently fed a normal diet and monitored for two months until
aortic dissection. Aortas of experimental animals were examined histologically for
the presence of C. pneumoniae coupled with immunofluorescent antibodies
specific to C. pneumoniae48. Minor, atherosclerotic lesions were observed at the
site of inoculation, and in the thoracic aorta. Researchers concluded from these
results that C. pneumoniae infections are capable of initiating lesions within the
aorta48.
Moazed et al. investigated the role of C. pneumoniae in atherogenesis
using apolipoprotein (apo) E-deficient transgenic mice that develop
atherosclerosis spontaneously, as well as C57BL/6J mice which will do so only
when fed an atherogenic diet49. Apo transgenic mice are considered an ideal
model for investigating the causative role of infectious agents in atherosclerotic
development, given that such mice undergo all biological processes observed in
atherosclerotic development in the absence of high fat and high cholesterol diets.
Sixty-eight male homozygous apoE-deficient mice were intranasally inoculated
with C. pneumoniae at 8, 10 and 12 weeks of age with standardized volumes of
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inoculum. Histological examination of the abdominal aorta at two weeks postinoculation revealed macrophage adherence to the endothelium, indicative of
early-stage atherosclerosis49. Histological examination of tissues mentioned
above at 4, 6 and 8 weeks post-inoculation revealed lesion progression from fatty
streak to early atheromas. C57BL mice, a genetically engineered strain of mice
that develop atherosclerosis only under an atherogenic diet, were treated under
similar experimental conditions. Immunohistochemistry, PCR, and isolation of C.
pneumoniae at different tissue sites were used to determine the affinity of C.
pneumoniae for atheromatous lesions. Moazed et al. determined that long-term
persistence of C. pneumoniae in the developing lesions within aortas of apoEdeficient mice, and not in C57BL mice, is evidence of a strong affinity between C.
pneumoniae and atheromatous lesions.49
Moazed et al. conducted an additional experiment to confirm the results
found in the experiment mentioned above. Again, the ability Chlamydia
pneumoniae to contribute to atherosclerosis in an apoE-deficient mouse was
investigated50. Twenty-one experimental animals were inoculated intranasally
with standardized inclusion forming units of C. pneumoniae 3 times, at 8, 9 and
10 weeks of age. Eighteen control animals were identically inoculated using
sterile PBS. Atherosclerotic lesions were observable along the inner curvature of
the aortic arch in both experimental and control animals. In the experimental
group, lesions were observed to be 2.4-fold greater in size 8 weeks after the first
inoculation and 1.6-fold greater in size at 20 weeks compared to control
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animals50. Moazed et al. asserted that such results clearly show that C.
pneumoniae contributes to the progression of atherosclerosis in apoE-deficient
mouse models50.
A study conducted by Campbell et al. reported similar results using apoEdeficient mice inoculated with C. pneumoniae 51. Mice of the C57BL/6J line were
fed a normal diet and inoculated with sterile SPG medium for comparison as
control animals. Mice were inoculated with C. pneumoniae intranasally using
standardized volumes of inclusion-forming units either singly, or at multiple time
points. Animals within the multi-inoculation experimental group received
inoculations at 8, 10 and 12 weeks, this same schedule was maintained for
C57BL/6J control animals receiving inoculations of sterile SPG medium.
Computer-assisted morphometric analysis was utilized to assess the size of
observed atherosclerotic lesions. Lesions within the aorta of repeat inoculation
treatment in apo-E deficient mice were observed to be 140% larger 6 weeks
post-inoculation, compared to apo-E deficient mice receiving a single inoculation.
No atherosclerotic lesions were detected within C57BL/6J controls.
Fong et al. conducted an experiment that inoculated twelve New Zealand
White rabbits via the nasopharynx with C. pneumoniae and five control rabbits
with carrier buffer52. Ten of 11 experimental animals exhibited serological
evidence of infection, in contrast with control animals that showed no
seroconversion. Experimental animals were sacrificed on days 7,14, 21 and 28
where controls animals were sacrificed on days 7 and 14. Importantly,
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histological examination of two rabbits within the experimental group showed
early signs of atherosclerosis. The first animal was sacrificed day seven post
inoculation and showed accumulation of foamy macrophages in the aortic arch52;
such findings are consistent with an early-stage atherosclerotic lesion in the form
of a fatty streak. The second experimental animal showing signs of
atherosclerosis was sacrificed day 14 post-inoculation and showed spindle cell
proliferation of smooth muscle cells, indicative of intermediate lesion formation.
All histopathological assessments were reported as negative for such lesions
within control animals52.
In a separate study, Fong et al. showed the ability of C. pneumoniae to
induce atherosclerosis in rabbits suffering from respiratory infections of C.
pneumoniae53. In this experiment, 23 animals were infected with C. pneumoniae
through the nasopharynx using a catheter and standardized test inoculums. A
total of thirty-six control animals were included in the study and inoculated with
sucrose phosphate glutamic acid (SPG) buffer (n=24) or HEp-2 cells and SPG
buffer (n= 12)53. Of interest, atherogenic changes were observed in the aortas of
6 of 23 experimental animals just three months after initial inoculation. A second
experimental group (n=24) was inoculated with C. pneumoniae, as described
above, three times within six weeks. It was noted upon histological examination
via light microscopy that within six weeks-time, the multiple inoculation
experimental group had grade III atherosclerotic lesions in 8 of 23 rabbits.
Atherosclerotic changes within controls animals inoculated with HEp-2 cells and
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carrier broth were not observed after three months of inoculation. Fong et al.
concluded from this result that C. pneumoniae may be important in the
pathogenesis of atherosclerosis in humans53.
Despite the overwhelming majority of experimental results indicating a
positive association between C. pneumoniae and atherosclerosis, a few studies
have been unable to replicate such findings. Caligiuri et al. experimented using
ApoE-KO mice, and C57BL/6J mice as controls, infecting both groups
intranasally with live C. pneumoniae and looking at the downstream effects on
arterial atherosclerosis 54. Thirteen ApoE-KO mice were infected once at age
eight weeks (n=13), and another subgroup of mice was inoculated a second time
(n=14) at age 16 weeks. Control C57BL6/J mice were inoculated once at age 8
weeks (n=8). All animals were fed a normal chow diet for 22 weeks after primary
infection. Polymerase chain reaction and ELISA were utilized to confirm
successful infection and a humoral immune response54. Aortas of all animals
were harvested, dissected, and atherosclerotic lesions were analyzed using
blinded lesion quantification as described55. Comparative analyses of
atherosclerotic lesions within the aortas between ApoE-KO groups and control
C57BL6/J group revealed no statistically significant differences54. It was also
noted that C. pneumoniae infection within wild-type C57BL6/J mice was unable
to produce significant atherosclerotic changes. Caligiuri et al. determined from
these results that C. pneumoniae does not induce atherosclerosis in wild-type
mice, nor is it capable of accelerating atherosclerosis in ApoE-KO mice54.
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Aalto-Setala et al. conducted a similar experiment using an ApoE-deficient
mouse, fed low or high-fat diets, inoculated intranasally with C. pneumoniae 3
times at one-week intervals 56. Ten control animals and ten experimental
animals inoculated with C. pneumoniae were kept on a regular chow diet.
Additionally, six control and four C. pneumoniae inoculated animals were fed a
high-fat diet. Control and experimental animals from both high-fat and low-fat
diet groups were sacrificed at 10 weeks post-initial inoculation. Aortic lesions
from all diets, experimental groups, and control groups samples were
histologically characterized for size. Importantly, it was noted that there was no
observable or significant difference in aortic lesion size in C. pneumoniae
infected or noninfected control mice from either low fat or high fat diets56. AaltoSetala et al. concluded that C. pneumoniae infection does not accelerate
atherogenic changes in experimental ApoE-deficient mouse models56.
Chlamydia pneumoniae, CVD, and Koch’s 4th Postulate:
Koch’s 4th postulate involves re-isolating the organism suspected of
causing disease, from an experimentally infected animal inoculated with the
suspect organism, manifesting the associated disease state. However, detection
via PCR, immunohistochemistry, serological testing, or ELISA, as opposed to
isolation, within the atherosclerotic tissues was observed in the majority of the
aforementioned studies 16, 36-43. Despite an extensive search, there are no
currently published studies that truly satisfy Koch’s 4th postulate in regards to C.
pneumoniae being the causative agent of atherosclerosis.
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Results
Chlamydia pneumoniae, CVD, and Koch’s 1st postulate:
Koch’s 1st postulate is one of the most logical steps in confirming a
suspect organism as the causative agent of a particular disease. During this
investigation, and an attempt to satisfy Koch’s 1st postulate, ten primary
investigations found within Pubmed were read in-depth and analyzed for relevant
information. The studies encompass a broad range of research parameters and
techniques, but similar in the attempts to detect C. pneumoniae within
atherosclerotic tissue. The results of these investigations is summarized in the
table below:
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Table 3: Summarized findings of studies showing detection of C. pneumoniae in atherosclerotic
tissue and/or serum. Of note, studies that utilized PCR to detect C. pneumoniae within
atherosclerotic tissues; For the satisfaction of Koch’s 1st postulate, PCR is the most definitive in
identifying C. pneumoniae within atherosclerotic tissue and elucidating the strong affinity of C.
pneumoniae for atheromas. CABG; *Coronary artery bypass grafting.
Primary
Sample
Tissue
Detection
Results/Findings/
Authors
Size
Collected
Methods
Association
Sessa et al41.

60 subjects
with aortic
atherosclerosis

atherosclerotic
tissue within
coronary arteries

*Semi-nested PCR

*No C. pneumoniae DNA
detected within controls

30 (controls
nonatherosclerotic
tissue)
Davidson et al36.

60 (low risk for
coronary artery
disease)

Atherosclerotic
tissue within
coronary arteries

ICC C. pneumoniae
specific monoclonal
antibodies
*PCR

Cho-Chou
Kuo17.

36 subjects

C. pneumoniae DNA detected in
31% (of 60)

Atherosclerotic
tissue within
coronary arteries

ICC

(+) Association between C.
pneumoniae and
atherosclerosis
C. pneumoniae detected in
raised atherosclerotic lesions-15
subjects
C. pneumoniae found within flat
lesions-7 subjects
(+) Association between C.
pneumoniae and
atherosclerosis
C. pneumoniae detected by ICC
in 15 of 36 subjects

*PCR
Electron microscopy

C. pneumoniae detected in 13 of
30 by PCR
Elementary bodies of C.
pneumoniae found in 6 of 21
harvested
atheromatous plaques

Agmon et al 42.

Altman et al43.

385 subjects

159 patients
(severe arterial
disease)

Aortic plaque
detection via
transesophageal
Echocardiography

Serum samples

Serology

(+) Association between C.
pneumoniae and
atherosclerosis
C. pneumoniae detected in 287
subjects

Species-specific
immunoglobulin
titers

C. pneumoniae not associated
with aortic plaques

Indirect
immunofluorescence

(-) Association between C.
pneumoniae and
atherosclerosis
C. pneumoniae detected in 107
patients in arterial group
Detected in 120 valvular group

203 patients
(heart valve
prosthesis

Clinical events for C.
pneumoniae (+) patients same as
(-)
(-) Association between C.
pneumoniae and coronary
artery disease
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Primary
Authors

Sample
Size

Tissue
Collected

Detection
Methods

Results/Findings/
Association

Hagiwara et al44.

50 samples

Carotid
atherosclerotic
plaques

*PCR

C. pneumoniae specific IgA
antibody detected in 24 samples,
29 for IgG

ICC
ELISA

C. pneumoniae detected in 8
samples via ICC
No C. pneumonia DNA detected
by PCR within plaques

Podsiadly et
al40.

188 patients
with
atherosclerosis

Serum

ELISA
*PCR

115 patients
without
atherosclerosis

(-) Association between C.
pneumoniae and
atherosclerosis.
IgG and IgA C. pneumoniae
specific antibodies detected in
63.8% and 49.0% atheroma
patients,
46.9% and 54.8% patients
without atherosclerosis
C. pneumoniae DNA detected via
PCR in atheromatous plaques
more than in vessels lacking
atheromatous lesions

Asar et al39.

Haider et al38.

85 patients
with CAD

63
cardiovascular
disease
patients

Atherosclerotic
tissue within
coronary arteries

Serum

*PCR

(+) Association between C.
pneumoniae and
atherosclerosis
C. pneumoniae detected in 25
out of 85 atherosclerotic tissues
via PCR and 5 out of 85 in
control tissues.

ELISA

(+) Association between C.
pneumoniae and
atherosclerosis
IgA antibodies for C. pneumoniae
detected in 42 out of 63
cardiovascular disease patients
and 12 out of 40 in controls.

*PCR

40 healthy
control patients

Izadi et al37.

105 patients
undergoing
*CABG
53 mamillary
artery samples

C. pneumoniae DNA was
detected via PCR was positive in
20 out of 63 cardiovascular
disease patients and none in
controls.

Atherosclerotic
tissue within
coronary arteries

*PCR

(+) Association between C.
pneumoniae and inflammation
C. pneumoniae DNA detected in
23 of 105 patients with coronary
artery atherosclerosis and none
found in mamillary artery controls
Significant portion of coronary
atherosclerotic plaques are
infected with C. pneumoniae
while no such infection was found
in controls.
(+) Association between C.
pneumoniae and
atherosclerosis
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Chlamydia pneumoniae, CVD, and Koch’s 2nd postulate:
Koch’s 2nd postulate entails the isolation, in the form of pure culture, of the
suspect organism from a diseased host. After intensive research within the
literature of PubMed, we determined that the isolation of C. pneumoniae from
atherosclerotic tissue has only been successfully accomplished twice. The low
success rate is due in part from the fastidious nature of C. pneumoniae and the
technical skills required for successful isolation. The findings/results of the two
studies are summarized in the table below:
Table 4: Summary of results and findings from primary investigations able to isolate C.
pneumoniae within atherosclerotic tissues.
Primary Sample
Tissue
Isolation Method Results/Findings/Associations
Author
Size
Collected
Ramirez
et al47.

12 patients
seeking heart
transplantations

Atherosclerotic
plaque from
coronary artery

Characterization of
isolates: PCR,
immunohistochemistry,
transmission electron
microscopy
Culture in HEp-2 Cell
monolayers.

Jackson
et al46.

25 patients
undergoing
Endarterectomy

Atherosclerotic
tissue from
carotid artery

Characterization of
isolate: PCR, southern
hybridization analysis,
reactivity with speciesspecific monoclonal
antibodies, electron
microscopy.
Culture in HeLa cell
monolayers

Bacterial culture grown in Hep-2 cell
monolayer-successful isolation from 1 of
12 patients/tissue samples
Isolate confirmed as C. pneumoniae via
species-specific antibody reactivity,
transmission electron
microscopy/observable elementary
bodies, and PCR.
(+) Association of C. pneumoniae and
atherosclerosis
Successful characterization and a single
isolation in 1 of 25 samples.
Isolate confirmed as C. pneumoniae via
PCR, southern hybridization analysis,
reactivity with species-specific
monoclonal antibodies. Importantly,
electron microscopy detected
elementary bodies present within
monolayer, consistent with C.
pneumoniae.
(+) Association of C. pneumoniae and
atherosclerosis

Chlamydia pneumoniae, CVD, and Koch’s 3rd postulate:
Koch’s 3rd postulate requires the inoculation of the suspect organism into
an experimental host and the genesis of disease. In this investigation, multiple
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studies demonstrated the ability of C. pneumoniae to induce atherosclerosis in
experimental animal models. The findings/results of the analyzed investigations
are summarized in the table below.
Table 5: Summary of research findings from studies analyzed aiming to demonstrate the
atherogenic ability of C. pneumoniae within animal models.;*ApoE; apolipoprotein E deficient
mice. *FVB mice; Friend leukemia virus B mouse. *C57BLK/6J; common inbred strain of
laboratory mouse.
Primary
Authors

Sample
Size

Animal
Models

Tissue
Collected

Detection
Methods for C.
pneumonia/
Atherosclerosis

Results/Findings/
Interpretations

Campbell et
al51

*ApoE KO =
43

ApoE-KO

Aorta

C. pneumoniae: ICC
and PCR

C. pneumoniae has a
tropism to developing
lesions present in
progressive
atherosclerotic
models51.

C57BL/6J
*C57BL/6J
=18

Aalto-Setala et
al56.

n/a

Atherosclerosis:
Computer-assisted
morphometric analysis
of lesion area

Apo-E KO

Aortic root

*FVB

Fong et al53.

Fong et al52.

46
experimental
animals 92
control
animals

12
experimental
animals

New Zealand
White Rabbits

Atherosclerosis:
histological
interpretation

Aorta

43
experimental
animals
8 controls

C. pneumoniae:
Immunohistochemistry,
serological testing
Atherosclerosis: Light
microscopy and lesion
classification

New Zealand
White Rabbits

Lungs, liver
spleen,
aortic arch

5 controls

Caligiuri et al54.

C. pneumoniae: PCR

C. pneumoniae:
Serology and
immunohistochemistry
Atherosclerosis:
Histological
interpretation

ApoE-KO

Root of
aorta and

C. pneumoniae: ELISA
and PCR

C57BLK6/J
Atherosclerosis:
Histology interpretation

(+) C. pneumoniae
can further aggravate
atherosclerosis
C. pneumonia infection
did not influence lesion
size in either mouse
strain56.
(-) Association: C.
pneumoniae not
capable of inducing
or aggravating
atherosclerosis
C. pneumoniae found
to induce
atherosclerosis in
rabbits53
(+) Association: C.
pneumoniae can be
atherogenic in animal
models
Rabbits within
experimental groups
demonstrated early,
intermediate lesions
not found in control
animals52
(+) Association: C
pneumoniae can be
atherogenic in animal
models
No statistical
differences in aortic
atherosclerotic lesions
between C.

34
Primary
Authors

Sample
Size

Animal
Models

Tissue
Collected

Detection
Methods for C.
pneumonia/
Atherosclerosis

Caligiuri et al54.
continued

Results/Findings/
Interpretations
pneumoniae infected
animals and controls54.
(-) Association: C.
pneumoniae not
capable of inducing
or aggravating
atherosclerosis

Moazed et al50.

Moased et al49.

Muhlsestein et
al48.

n/a

Apo-E KO

68 ApoE-KO

ApoE-KO

74 C57Bl/6J

C57BLK6/J

n/a

Rabbits

Aorta
(curvature of
aortic arch)

Lung,
Spleen,
Ascending
and
abdominal
aorta

Aorta

C. pneumoniae: n/a
Atherosclerosis:
morphometric analysis

C. pneumoniae:
Serology and PCR
Atherosclerosis:
Histological
interpretation

C. pneumoniae: Direct
immunofluorescence
Atherosclerosis:
Histological
interpretation

Results show that C.
pneumoniae infection
accelerates
progression of
atherosclerosis in ApoE KO mouse models50.
(+) Association: C
pneumoniae can be
atherogenic in animal
models
C. pneumoniae were
detected in the aorta 2
weeks after a single
inoculation; suggestive
of a tropism of C.
pneumoniae to
atherosclerotic
lesions49
(+) Association: C.
pneumoniae may be
atherogenic in animal
models
C. pneumoniae
infection is capable of
aortic lesions where
they do not otherwise
occur48.
(+) Association: C.
pneumoniae may be
atherogenic in animal
models

Chlamydia pneumoniae, CVD, and Koch’s 4th postulate:
Koch’s 4th postulate entails the re-isolation, in pure culture, of the
infectious organism from an experimentally infected animal. Despite extensive
research within the literature in PubMed, no such experiment or process was
found within the literature.
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Discussion
The goal of this paper was to use Koch’s postulates as guidelines to
determine if C. pneumoniae is a risk factor for cardiovascular disease. Exposure
to C. pneumonia is common and the presence of C. pneumoniae antibodies
within serum does not necessarily indicate infection. For this reason, many of the
studies reviewed in this investigation utilized C. pneumoniae antibody detection
in conjunction with other detection methods. Polymerase chain reaction is
considered a reliable method for detection of C. pneumoniae within
atherosclerotic tissues.
Koch’s 1st postulate: Microorganisms should be found in heavy abundance
in all disease hosts, and absent in healthy organisms. In alignment with
Koch’s 1st postulate, the results of studies analyzed in this investigation
demonstrate a high prevalence of C. pneumoniae within atherosclerotic tissue.
Kuo et al. found an association through detection of C. pneumoniae in
atherosclerotic tissue using PCR, ICC and electron microscopy that revealed
pear-shaped bodies within atheromatous tissues17; the finding of pear-shaped
bodies is indicative of viable bacteria living within host tissue. The affinity of C.
pneumoniae for atherosclerotic tissue was demonstrated by Izadi et al. using
PCR to detect C. pneumoniae within atherosclerotic tissue harvested from
coronary arteries. Chlamydia pneumoniae DNA was detected in 21.9% of
samples tested and was not found in control samples37. The results reported by
Izadi et al. were similar to those reported by Assar et al. who used PCR to detect
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C. pneumoniae within atherosclerotic, and non-atherosclerotic tissues.
Chlamydia pneumoniae was found in 25 of 85 atherosclerotic tissue samples
compared to just 5 of 85 non-atherosclerotic tissue samples39. Sessa et al. also
used PCR to detect C. pneumoniae within atherosclerotic tissues samples and
found C. pneumoniae DNA present in 19 of 60 samples; no such DNA was found
in 30 non-atherosclerotic control samples41. In total, seven of ten studies
reviewed detected statistically significant greater numbers of C. pneumoniae
within cardiovascular disease groups or tissues, compared to controls. Five of
the seven above studies successfully detected C. pneumoniae directly within
atherosclerotic tissues via PCR (17, 36, 37, 39, 41) . However, three of the studies
reported no such detection compared to non-atherosclerotic controls37, 38, 41 .
Further evidence of the association between C. pneumoniae and
atherosclerosis was provided by serological data collected by Podsiadly et al.
using ELISA for IgA and IgG antibodies to the bacteria40. Serum samples were
collected from atherosclerotic patients and compared with that of nonatherosclerotic patients for the presence of species-specific antibodies. The
prevalence of C. pneumoniae antibodies was reported as statistically greater
within atherosclerotic patients when compared to non-atherosclerotic patients40.
The results of Podsiadly et al. again show the association of C. pneumoniae with
atherosclerosis.
In total, of the ten studies relevant to Koch’s 1st postulate that were
reviewed, C. pneumoniae DNA was detected within atherosclerotic tissue
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samples in 195 of 641 tested samples, equivalent to 30.42%. Analysis of this
review reveals, in total, C. pneumoniae was detected in atherosclerotic tissue by
electron microscopy in 6 of 21 samples17, by serology in 287 of 385 serum
samples42, by ICC in 38 of 146 samples17, 36, 44, and by indirect
immunofluorescence in 107 out of 159 samples43. Additionally, in total, IgA
antibodies were detected via ELISA in 158 of 301 atherosclerotic samples.
Similarly, analysis of all ten studies revealed total IgG antibodies detection via
ELISA in 149 of 238 atherosclerotic samples38, 40, 44. Although the above values
do not illustrate a causative relationship, it nonetheless should be noted that C.
pneumoniae and atherosclerosis are frequently found together.
Three of ten studies analyzed relevant to Koch’s 1st postulate asserted
that C. pneumoniae was not associated with atherosclerotic tissues42-44. It is
hypothesized that this lack of association is due to technical difficulties in
harvesting samples, limited sample sizes, laboratory errors in detection, or
factors unbeknownst to researchers.
The majority of aforementioned studies detected C. pneumonia within
atherosclerotic tissues compared to nonatherosclerotic controls, and found a
positive association between C. pneumoniae and atherosclerotic tissue. Because
C. pneumoniae was not found within every occurrence of atherosclerosis, and
was found in some healthy individuals, satisfying of Koch’s 1st postulates is not
possible. This is not unexpected, especially when considering the multifaceted
process, and associated multitude of risk factors, involved in the development of
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artherosclerotic plaques. However, the evidence provided, and frequent detection
of C. pneumoniae within atherosclerotic tissue, clearly shows the affinity of C.
pneumoniae for atherosclerotic tissue not to be a random occurrence, but an
associative phenomenon, and suggests infection with C. pneumoniae is indeed a
risk factor for CVD.
Koch’s 2nd postulate: Microorganism must be isolated from diseased host,
and grown in pure culture. As previously mentioned, C. pneumoniae is a very
difficult organism to grow in the laboratory, and therefore it may be challenging to
provide considerable evidence that supports Koch’s 2nd postulate regarding C.
pneumoniae and cardiovascular disease. However, a search of the literature
clearly shows that although arduous, isolation for C. pneumoniae from a
diseased organism is possible46, 47. One must also consider the overwhelming
amount of C. pneumoniae detected via PCR, ELISA, immunohistochemistry, and
serological methods as an indication that viable organisms are present within the
diseased host tissues. The evidence within the literature demonstrates that
isolation of C. pneumoniae from a diseased host is possible as outlined by
Koch’s 2nd postulate.
Koch’s 3rd postulate: Microorganism must cause associated disease when
introduced into healthy organism. Koch’s 3rd postulate is perhaps the most
significant in asserting that a suspect infectious agent is capable of causing
disease. The postulate states that the inoculum must come from a pure culture
isolated from an infected host, be inserted into a healthy experimental host, and
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cause disease. However, given the limited number of studies that have been able
to isolate C. pneumoniae and grow it in pure culture, a modified version of this
postulate must be considered for this analysis; any viable culture of C.
pneumoniae will suffice to serve this purpose. This investigation analyzed a total
of eight studies that aimed to uncover the atherogenic capabilities of C.
pneumoniae in animal models. Fong et al. inoculated a total of 58 New Zealand
White rabbits with C. pneumoniae and compared these to 97 control animals;
Fong et al, successfully demonstrated the atherogenic capability of C.
pneumoniae in rabbit models 53, 57. Additionally, a total 154 ApoE-deficient mice
in three of the aforementioned studies were inoculated with C. pneumoniae
under varying, but similar, conditions and compared to 100 control animals; all
three studies found C. pneumoniae to be atherogenic when compared to control
animals49, 51, 54. In total, six of the eight studies presented definitive evidence of
C. pneumoniae as capable of inducing or aggravating atherogenesis in animal
models when compared to controls48-53.
Research conducted by Caligiuri et al. was unable to reproduce the
atherogenic capabilities of C. pneumoniae within Apo-E deficient mice54;
research conducted by Aalto-Setala et al. yielded similar results56. It is difficult to
ascertain why C. pneumoniae was unable to produce or aggravate atherogenesis
in experimental conditions so similar to the successful studies described above.
One possibility could be differences in the metabolic activity of the bacterium at
the time of inoculation. Bacteria in the exponential phase of growth are most
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metabolically active and capable of causing infection. It is possible that at the
time of inoculation, C. pneumonia was not at peak metabolic activity, and
therefore unable to gain a foothold within the host. The expression of virulence
factors also plays a significant role in the success of an infectious agent. It is
possible that important virulence factors where not being expressed at the time of
inoculation, unbeknownst to researchers. A future study that confirmed genetic
expression profiles using microarrays before inoculation may be warranted to
ensure successful infection; this could bring uniformity to the experimental
results. Taken together, the experimental results within those studies mentioned
above demonstrate the atherogenic ability of C. pneumoniae within animal
models, and correspond with the criteria outlined by Koch’s 3rd postulate.
Koch’s 4th postulate: Microorganism must be re-isolated from diseased,
experimental host and determined to be identical to original causative
agent. As previously stated, despite an extensive search within the literature of
Pubmed, no experiments were found that would correspond to Koch’s 4th
postulate. Such a task would entail inoculating a healthy host with C.
pneumoniae, inducing measurable and statistically significant occurrences of
atherosclerosis, and re-isolating the C. pneumoniae in pure culture. The
challenges associated with isolating C. pneumoniae in pure culture make this
task unlikely to succeed. However, establishing a causative relationship between
C. pneumoniae and atherosclerosis/cardiovascular disease is not dependent on
the starkly demarcated criteria of Koch’s postulates, but upon the interpretation of
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experimental results that use Koch’s postulates as guidelines to establish a
causative relationship.
Another important consideration when interpreting the results of each
study, and the conclusions of this paper, is the possibility that initial infections by
C. pneumoniae may initiate a cascade of immune responses within the infected
host. The downstream of effects of such elicited immune responses could
include, among other things, the genesis or aggravation of atherosclerosis. As
with many infectious diseases, the immune system can respond in ways that are
damaging to the body and are not always overtly obvious to researchers. With
this consideration in mind, it is possible that atherosclerosis is a secondary
consequence of infection by C. pneumoniae and not, a direct result of C.
pneumoniae infection, and thus can occur after the C. pneumoniae is no longer
present.
From around 1990 to 2005, Chlamydia pneumoniae was at center stage
regarding biomedical research concerning the role it may play in cardiovascular
disease. After 2005, there was stark drop-off in research conducted to establish a
causative relationship between C. pneumoniae and CVD. It is possible that this
drastic reduction was due to the fact there were hundreds of experiments that at
a minimum, detected C. pneumoniae within atherosclerotic tissue and concluded
that the two may therefore be associated with one another. It is possible, that
from a clinical perspective, there has been enough research to support C.
pneumoniae infection as a plausible risk factor for atherosclerosis and CVD, and
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therefore no more research is warranted to further solidify the relationship
between C. pneumoniae and CVD.
Within this investigation, C. pneumoniae was shown to be present in
abundance in atherosclerotic tissues and patients with cardiovascular disease17,
36-41

. Although in a limited capacity, C. pneumoniae has been isolated in pure

culture from hosts who have atherosclerosis and cardiovascular disease.
Additionally, C. pneumoniae demonstrated the ability to induce or aggravate
atherosclerosis within animal models 46-53. This investigation demonstrated a an
association between C. pneumoniae and atherosclerosis/CVD through the use of
Koch’s postulates as guidelines. Future directions should include improving
isolation techniques by assessing the efficacy of different mammalian cell lines in
the passage of C. pneumoniae. Such an assessment may lead to improved
passage techniques and congruence with Koch’s 4th postulate. Future studies
should also include antibiotic treatment of C. pneumoniae within animal models
to determine if prophylactic treatment is warranted to attenuate the
atherosclerotic process. Analysis and review of all experimental results
summarized in this study suggest that Chlamydiae pneumoniae should be
considered a risk factor for atherosclerosis and cardiovascular disease.
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